Kathleen A. Rickard - May 1, 2023 Form 4/A - Amendment Insider Report for Verona Pharma plc (VRNA)

Role: Chief Medical Officer
Signature: /s/ Claire Poll, Attorney-in-fact for Kathleen A. Rickard
Stock symbol: VRNA
Transactions as of: May 1, 2023
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 5/11/2023, 04:15 PM
Date Of Original Report: May 3, 2023
Previous filing: Feb 3, 2023
Next filing: Aug 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRNA	Ordinary Shares	Options Exercise		+15K	+0.5%		2.99M	May 1, 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRNA	Restricted Share Units	Options Exercise	$0	-15K	-100%	$0.00^*	0	May 1, 2023	Ordinary Shares	15K		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Reported securities are represented by American Depositary Shares ("ADSs") (unless otherwise indicated), each of which represents eight (8) Ordinary Shares of the Issuer.
F2	Each Restricted Share Unit represented a contingent right to receive one (1) Ordinary Share of the Issuer (which may be represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer) subject to certain time- and performance-based vesting criteria.
F3	Consists of (i) 1,743,488 Ordinary Shares underlying Restricted Share Units (each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer) (which are represented by 217,936 ADSs); and (ii) 1,242,648 Ordinary Shares underlying 155,331 ADSs.

Remarks:

This Form 4/A is being filed to report the vesting of certainly previously reported Restricted Share Units which was inadvertently omitted in the Form 4 filed on May 3, 2023. The aggregate total in column 5 of Table I hereof reflects the total aggregate holdings after accounting for the sales reported in the Form 4 filed on May 3, 2023.